Hiroyuki Katoh is a Professor of Medical Education and Chair of International Relations at Tokai University School of Medicine, Kanagawa, Japan, where he also serves as Vice Director of the Education Planning Center. He holds board certifications as an Orthopaedic Surgeon, Spine Surgeon, and Spine Surgery Specialist. Dr. Katoh earned his M.D. from Keio University School of Medicine in 2000 and his Ph.D. in Medicine from the same institution in 2012. His doctoral research focused on the neural crest origin of the peripheral olfactory system and spinal cord injury pathophysiology. Following orthopaedic surgery residency at Keio, he pursued basic science research in the Department of Physiology at Keio University (2004–2006) under the mentorship of Prof. Hideyuki Okano, investigating neural stem cell transplantation for spinal cord injury, with publications in Nature Medicine, PNAS, Cell Stem Cell, and FASEB Journal. In 2018–2019, he completed a research fellowship at the Krembil Neuroscience Centre, Toronto Western Hospital, under Prof. Michael G. Fehlings, furthering his expertise in spinal cord injury translational research. His current research interests include spinal cord injury pathophysiology, ossification of spinal ligaments, neuropathic pain assessment, and cervical myelopathy outcomes. He has been a member of the Japanese Ministry of Health, Labour and Welfare's Intractable Disease Research Group on Ossification of Spinal Ligaments since 2013 and has received three consecutive JSPS KAKENHI grants. Dr. Katoh has authored over 190 peer-reviewed publications (h-index: 24), including 7 book chapters. He has been a member of the International Spinal Cord Society since 2014 and received the English Presentation Award at the 53rd Annual Meeting of the Japanese Society for Spine Surgery and Related Research in 2024. He is dedicated to international medical education, having established multiple exchange agreements with partner institutions across Asia.

Dr Jenny Lisshammar is a Clinical Neuropsychologist in the Departments of Neurology and Rehabilitation at Sahlgrenska University hospital. She is also a postdoctoral researcher at the University of Gothenburg. Her research interests include neuropsychological sequelae of spinal cord injury, as well as preventive service delivery and equity in healthcare for individuals with cord injury.

Dr Nicolas Serratrice is a neurosurgeon and physician–scientist specializing in spinal cord injury and translational neurotrauma. He completed a dual medical and scientific training (MD–PhD), combining clinical neurosurgery with rigorous experimental research in spinal cord pathophysiology and regenerative strategies. This integrated background underpins his work at the intersection of acute surgical management and biologically targeted therapeutic development. He currently co-directs the CT-MEP (Centre Thérapeutique de la Moelle Épinière et de ses Pathologies), a multidisciplinary center dedicated to the comprehensive management of spinal cord injury and complex spinal cord disorders. Within this framework, he has contributed to the development of translational programs integrating advanced imaging, neurophysiological monitoring, experimental modeling, and innovative regenerative approaches. His research focuses on redefining the acute phase of contusive spinal cord injury as a time-sensitive therapeutic window. Through coordinated preclinical rodent and large-animal studies, biological standardization frameworks, and surgical delivery optimization, his work aims to structure the bench-to-clinic translation of autologous cell-based interventions. He has authored and co-authored peer-reviewed publications addressing spinal cord injury anatomy, intraparenchymal precision delivery, stromal vascular fraction standardization, and safety evaluation of autologous regenerative therapies. Dr Serratrice’s current academic objective is to integrate biologically targeted interventions within contemporary surgical workflows and to design rigorously controlled early-phase clinical trials in spinal cord injury. His work reflects a commitment to bridging surgical excellence with translational neuroscience in order to expand therapeutic perspectives in acute neurotrauma.

Dr Ronak Reshamwala is a Senior Research Fellow with the Clem Jones Centre for Neurobiology and Stem Cell Research at the Institute for Biomedicine and Glycomics, Griffith University, Australia. Dr Reshamwala is in charge of the preclinical translational reserach as well as clinical research being done under the Spinal Injury Project (SIP) within the Centre, and leads the neurosurgery research team. He is a medical doctor trained in India and has received his PhD from the Griffith University, Australia. He combines his clinical training and keen reserach acumen to develop clinically valid applications for promising biotenchnological advances and research. Dr Reshamwala's main research interests include translational research, regenerative neurology, spinal cord injury, neurodegeneration and pain perception. His PhD work focused on developing novel approaches or transplantation of 3D cellular constructs in the injured spinal cord to induce structural and functional repairs. He is currently working on developing better translatable and robust surgical approaches as well as behavioural tests for treating and assessing spinal cord injuries. Dr Reshamwala's success in this project has played a pivotal role in bringing this technology as a potential therpay for spinal cord injury repair to the Phase I/IIa clinical trial set to be launched in 2024. Consumer and community engagement as well as public outreach are significant parts of Dr Reshamwala's research work; interacting with community and clinicians, and bringing them together to co-design clinical applications and their testing approaches (clinical trials) which helps maximise the impact. Recently, Dr Reshamwala was awarded a three-year fellowship by the National Injury Insurance Scheme Queensland (NIISQ) to work on the next generation of our team's ground-breaking nerve bridge technology for spinal cord repair to further enhance the effectiveness and to bring the therapy to meet the expectations of the community as well as clinicians.